Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani(Swiss Group For Clinical Cancer Research), Prudence A. Francis(Peter MacCallum Cancer Centre), Fabio Puglisi(University of Udine), Sherene Loi(The University of Melbourne), Claudio Chini(Aziende Socio Sanitarie Territoriale dei Sette Laghi), Meredith M. Regan(Dana-Farber Cancer Institute), Barbara Ruepp(The Coordinating Center), Barbara Walley, Richard D. Gelber(Harvard University), Gini F. Fleming(University of Chicago Medical Center), Carlo Tondini(Ospedale Papa Giovanni XXIII), Henry Gómez(National Cancer Center), Marco Colleoni(European Institute of Oncology), Harold J. Burstein(Dana-Farber Cancer Institute), Vered Stearns(Johns Hopkins University), Hervé Bonnefoi, Charles E. Geyer(Magee-Womens Hospital), Simon Spazzapan(Centro di Riferimento Oncologico), Eric P. Winer(University of Vermont), Alan S. Coates(International Breast Cancer Study Group), Eva Ciruelos(Hospital Universitario 12 De Octubre), István Láng(National Institute of Oncology), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Thomas Ruhstaller(University Hospital Bonn), Silvana Martino(Angeles Clinic and Research Institute), Matthew P. Goetz(Mayo Clinic)
Cited by 159
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k